ArticlePeerJ2025
Liver stiffness and serum galectin 3 level significantly increases in patients with prediabetes: a fibroscan study.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Galectin-3 in Liver Inflammation and Fibrosis.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Diabetes mellitus (DM) is associated with the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). In our study, we aimed to evaluate the relationship between liver stiffness (LS) and galectin-3 levels in patients diagnosed with prediabetes. Methods: A total of 120 participants were included in this prospective and cross-sectional study, comprising 40 patients with prediabetes, 40 patients with type 2 DM and 40 individuals with normal glucose metabolism. Human galectin-3 levels were measured using Enzyme-Linked Immunosorbent Assay (ELISA) with Human Galectin-3 kits. LS measurements were performed using the FibroScan® Mini 430 device (Echosens, France). Results: In our study, we found that Fib-4 index, LS and galectin-3 levels were increased in patients with prediabetes. Another significant finding was that hemoglobin A1c (HbA1c) and galectin-3 levels were higher in patients with LS value ≥8 kPa and both HbA1c and galectin-3 levels were independently associated with LS. Conclusion: Considering the increased prevalence of MASLD in prediabetes, we recommend early assessment of LS and measurement of galectin-3 levels in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.